- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.11. | Two former Alexion leaders fight through a tough market to sustain a rare disease biotech | ||
| 05.11. | Sana to lay off staff, deepen autoimmune focus in latest retrenchment | ||
| 05.11. | Sickle cell patient dies in Beam study of base editing therapy | ||
| 04.11. | Neurogene secures $200M ahead of anticipated study readout | ||
| 04.11. | Viking data provide latest test of oral obesity drug potential | ||
| 04.11. | Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs | ||
| 04.11. | Centers of excellence or product-centric BizDevOps managed services? | ||
| 04.11. | Empowering versatile applications of digital PCR with standardized, validated assays | ||
| 01.11. | Novo, with new results, to seek approval for obesity drug in MASH | ||
| 01.11. | Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug | ||
| 31.10. | Roche weighs whether speedy approval path is open for latest Alzheimer's drug | ||
| 31.10. | FDA's new device chief faces challenges. Patient groups, industry are still optimistic. | ||
| 31.10. | Jade, another biotech spinout of Paragon, to merge with Aerovate | ||
| 31.10. | Compass delays anticipated psilocybin readout, cuts staff | ||
| 31.10. | Evommune raises $115M to accelerate immune drug tests | ||
| 30.10. | Novo takes big step toward ending Ozempic, Wegovy shortages | ||
| 30.10. | GSK vaccine sales sink on lower demand for RSV, shingles shots | ||
| 30.10. | Investors put $115M into Axonis amid revived interest in brain drugs | ||
| 30.10. | Biogen, Sage admit a defeat in major depression | ||
| 30.10. | Biogen optimistic as new products gain traction | ||
| 30.10. | Lilly shares fall as obesity drug sales miss forecasts | ||
| 30.10. | A new biotech, built around protein design, springs from David Baker's lab | ||
| 29.10. | Pfizer sales of RSV vaccine ebb, but company gains market share | ||
| 29.10. | Paragon spinout joins hunt for new type of cancer immunotherapy | ||
| 29.10. | GSK to pay $300M to license drug it sees as potential lupus treatment |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
